Final results from the first-in-human phase 1/2 study of modakafusp alfa, an immune-targeting attenuated cytokine, in patients (Pts) with relapsed/refractory multiple myeloma (RRMM)
Last Updated: Tuesday, July 11, 2023
This report shares the final safety and efficacy results, including minimal residual disease status, from parts 1 and 2 of a study on modakafusp alfa, a first-in-class, immune-targeting, attenuated cytokine.
Advertisement
News & Literature Highlights